Zacks Research Research Analysts Lift Earnings Estimates for Omnicell, Inc. (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Investment analysts at Zacks Research lifted their Q2 2025 EPS estimates for shares of Omnicell in a note issued to investors on Tuesday, September 10th. Zacks Research analyst U. Biswas now anticipates that the company will earn $0.14 per share for the quarter, up from their prior estimate of $0.13. The consensus estimate for Omnicell’s current full-year earnings is $0.64 per share. Zacks Research also issued estimates for Omnicell’s Q2 2026 earnings at $0.30 EPS and FY2026 earnings at $0.72 EPS.

A number of other research firms have also commented on OMCL. Wells Fargo & Company raised their price target on shares of Omnicell from $26.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Friday, August 2nd. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Wednesday. Barclays upgraded shares of Omnicell from an “underweight” rating to an “equal weight” rating and lifted their price target for the company from $26.00 to $39.00 in a research report on Friday, August 2nd. JPMorgan Chase & Co. increased their price target on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a research report on Friday, August 23rd. Finally, Benchmark restated a “buy” rating and set a $38.00 price objective on shares of Omnicell in a research note on Monday, July 15th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, Omnicell presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.83.

Omnicell Stock Down 0.6 %

OMCL stock opened at $42.83 on Wednesday. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $56.06. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.45 and a quick ratio of 2.22. The stock has a market capitalization of $1.97 billion, a price-to-earnings ratio of -93.11, a PEG ratio of 50.19 and a beta of 0.83. The business’s fifty day moving average price is $37.09 and its two-hundred day moving average price is $31.52.

Omnicell (NASDAQ:OMCL) last posted its earnings results on Thursday, August 1st. The company reported $0.51 EPS for the quarter, beating the consensus estimate of $0.14 by $0.37. The company had revenue of $276.80 million for the quarter, compared to the consensus estimate of $254.41 million. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The firm’s revenue for the quarter was down 7.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.29 earnings per share.

Hedge Funds Weigh In On Omnicell

A number of institutional investors have recently modified their holdings of OMCL. Arizona State Retirement System increased its position in Omnicell by 2.9% during the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after purchasing an additional 357 shares in the last quarter. Texas Permanent School Fund Corp grew its stake in shares of Omnicell by 1.2% during the first quarter. Texas Permanent School Fund Corp now owns 39,630 shares of the company’s stock worth $1,158,000 after buying an additional 479 shares during the last quarter. Diversified Trust Co increased its holdings in shares of Omnicell by 3.3% during the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock worth $416,000 after buying an additional 494 shares in the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Omnicell by 2.7% in the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock valued at $625,000 after acquiring an additional 600 shares during the last quarter. Finally, ProShare Advisors LLC boosted its holdings in shares of Omnicell by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after acquiring an additional 626 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.